BsAbs Targeting Immune Cells

Creative Biolabs is one of the leading international companies in the field of bispecific antibodies (BsAbs) service. We have developed multiple advanced BsAb engineering/ production platforms and are dedicated to providing our customers satisfying BsAb targeting immune cells.

In recent years, scientists have gained more and more interest in the development of BsAbs that can employ immune cells to fight against different kinds of tumor or immune diseases. Comparing to common antibodies, BsAbs can bind two targets simultaneously and thus bring these targets in proximity. Specific BsAbs can retarget immune cells to tumor cells and induce anti-tumor immune responses, including T-cell mediated cell death, antibody-dependent cellular cytotoxicity (ADCC) and/or phagocytosis.

Figure 1. Various bsAbs are currently in clinical development and some are developed for targeting immune cells. (Kontermann, R. E., 2015)

BsAbs Targeting Immune Cells

It has been known for a long time that antibodies are able to recruit effector cells (e.g., monocytes, natural killer cells) of the immune system to target cells and induce immune responses that eventually kill the target cells. However, there are several limitations of conventional monospecific antibodies. First of all, these antibodies cannot employ effector cells that lacking the Fc receptors. Cytotoxic T lymphocyte, one of the most powerful components of the immune system, is one of them. Secondly, the binding of conventional antibodies to Fc receptors is nondistinctive. To be specific, they bind also to non-activating Fc receptors, inhibitory Fc receptors, and Fc receptors on non-cytotoxic cells. What’s more, conventional therapeutic antibodies have to compete with natural immunoglobulins in the system for binding of the Fcγ receptor I. Bispecific antibodies can selectively retarget potent immune cells to tumor cells by binding to a tumor-associated antigen with one arm and an receptor on the effector cell with the other arm.

Creative Biolabs has spent years to develop a professional BsAb research team with advanced antibody engineering platforms. Now we have unbeatable technology and team in the field of BsAb services. Here customers can get customized, one-stop, high-quality, time-saving and budget-saving services for the design, manufacture, and characterization of BsAbs.

References

1. Baty, D. Bispecific effector-cell engagers, novel immunotherapeutics trained to fight cancer. Medicographia. 2015, 37: 271-279.
2. Bassan, R. Toward victory in adult ALL: blinatumomab joins in. Blood. 2012, 120(26): 5094-5095.
3. Kontermann, R. E.; Brinkmann, U. Bispecific antibodies. Drug discovery today. 2015, 20(7): 838-847.